INTRODUCTION
Mantle cell lymphoma (MCL) is an aggressive B cell malignancy, which represents 5-10% of non-Hodgkin lymphomas. The median overall survival is 3-5 years and, at present, conventional treatment is not curative and long-term remission is rare.
However, subsets of MCL patients follow a more indolent clinical course without disease progression for a relatively long period 1 .
The cytogenetic hallmark of MCL is the chromosomal translocation t(11;14)(q13;q32).
This aberration leads to the juxtaposition of the CCDN1 locus on chromosome 11 to the immunoglobulin heavy chain (IGH) locus on chromosome 14. As a consequence, cyclin D1 is constitutively over-expressed causing gross cell-cycle deregulation 2 . In addition to the primary t (11;14) , a number of secondary genomic aberrations can be identified in most MCL cases [2] [3] , supporting early findings that cyclin D1 over-expression must be accompanied by other genetic abnormalities in order to promote lymphomagenesis 2, 4 .
Various gene expression changes that may cooperate with cyclin D1 deregulation have also been described in MCL, mainly involved in DNA repair pathways and the control of cell cycle and apoptosis [4] [5] . That notwithstanding, alterations in the local tumor microenvironment may also play an important role in regulating the growth and survival of MCL neoplastic cells 2, [5] [6] .
In B cell malignancies, immunogenetic analysis of the clonogenic B cell receptors (BcRs) offers valuable insight into both the ontogenetic derivation and the possible involvement of antigen selection. In particular, a biased repertoire of immunoglobulin heavy variable (IGHV) genes is generally considered as evidence for the involvement of a limited set of antigens and/or superantigens in lymphoma development [7] [8] . In addition, many B cell lymphomas exhibit somatic hypermutation (SHM) patterns in IGHV genes, typical of antigen receptors that have undergone selection by antigen [9] [10] . For certain lymphomas, most notably chronic lymphocytic leukemia (CLL), the involvement of antigens in lymphomagenesis is further supported by the identification of closely homologous antigen binding sites between unrelated cases ("stereotyped" BcRs) 11 .
Studies of the immunoglobulin (IG) gene repertoire in MCL have demonstrated biases,
with a preferential use of the IGHV4-34, IGHV3-21 and IGHV3-23 genes. However, their relative frequencies differed between studies, most likely due to relatively small cohort sizes (the largest available study included 141 cases) [12] [13] [14] [15] [16] [17] . Moreover, there is evidence
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All relevant studies consistently showed that in the majority of MCL cases the clonotypic IGHV genes were either unmutated or exhibited a low impact of SHM activity. Based on this and other observations, the cellular origin of MCL was traced to a stage of B cell development prior to the transition through the germinal center (GC) [13] [14] . This view was adopted by the 2008 WHO Classification that considers "the postulated normal counterpart of MCL B cell {as} a peripheral B cell of the inner mantle zone, mostly of naïve pre-germinal center type" 19 .
Against this, virtually all aforementioned studies have reported the existence of a subset of MCL patients with mutated IGHV genes, variably accounting for 16% to 38% of cases [12] [13] [14] [15] [16] [17] [18] . This poses a conundrum, given the prevailing views about MCL ontogeny. In all studies, assignment to the "mutated" IGHV subset followed the 2% cut-off value for deviation from the closest IGHV germline gene, which is widely used for prognostication in CLL 20 . Accordingly, IGHV-mutated status was appointed to rearrangements only when the germline identity (GI) was below 98%, thereby giving little if any attention to cases with IGHV genes carrying a few mutations, leading to greater than 98% but less than 100% GI. From a biological perspective, this may be an oversimplification, in view of ample evidence from normal, autoreactive and malignant B cell clones where even a low mutational "burden" can be functionally relevant 9, [21] [22] .
In the present study, we performed a detailed immunogenetic analysis of the IG receptors from 807 cases with MCL, by far the largest series to date. Our aim was to obtain a comprehensive view of the IG gene repertoire, with a special focus on SHM targeting and the configuration of the antigen-binding site. We here report that MCL is characterized by a highly selective IG gene repertoire and very precise SHM targeting.
We also document for the first time the existence of subsets of cases with stereotyped BcRs and disease-biased molecular features, distinct from those previously reported in other B cell malignancies, especially CLL. On this evidence, we propose an antigendriven origin of MCL, at least for certain subsets of cases.
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PATIENTS AND METHODS

Patient group
A total of 807 patients with a diagnosis of MCL from collaborating institutions in France (n=132), Germany (n=270), Greece (n=56), Italy (n=22), the Nordic countries (Denmark, Finland, Norway, and Sweden; n=266), Spain (n=39) and the Netherlands (n=22) were included in the study. The diagnosis was established according to the 2008 World Health Organization Classification criteria 19 . The study was approved by the local Ethics Review
Committee of each institution.
PCR amplification of IGHV-IGHD-IGHJ rearrangements
PCR amplification of IGHV-IGHD-IGHJ rearrangements was performed on either genomic DNA (gDNA) or complementary DNA (cDNA), extracted mainly from fresh blood and bone marrow aspirates, but also from fresh and formalin-fixed, paraffinembedded solid tissue specimens, including lymph nodes, bone marrow biopsies, spleen, orbit and colon.
In the case of fresh or fresh-frozen samples, PCR amplification of IGHV-IGHD-IGHJ rearrangements was performed using IGHV leader primers or consensus primers for the IGHV FR1 region along with appropriate IGHJ gene primers, as previously described 9, 12, [15] [16] [17] or following the BIOMED-2 protocol 23 . In the case of formalin-fixed, paraffin-embedded material, deparaffinization was done according to standard methods and gDNA was extracted using the QIAamp Tissue Kit (Qiagen, Hilden, Germany)
following the manufacturer's recommendations. PCR amplification of IGHV-IGHD-IGHJ rearrangements was performed with a seminested approach, using the same IGHV FR1
or, in 61/807 cases (7.6% of the cohort), IGHV FR2 5' consensus primers in both amplification rounds along with two different IGHJ 3' consensus primers, of which that used in the second round was more internal.
Sequence analysis and interpretation
PCR amplicons were subjected to direct sequencing on both strands. Sequence data were analyzed using the IMGT® databases [24] [25] and the IMGT/V-QUEST tool (http://www.imgt.org) 26 . Codons and amino acid positions are according to the IMGT unique numbering for V domain 27 . In order to avoid misidentification of mutations when IGHV FR1 or FR2 consensus primers were used in the amplification reactions, nucleotide substitutions in the obtained sequences were evaluated from codon 27 in CDR1-IMGT or, in those sequences obtained with a VH FR2 primer, codon 56 in CDR2-IMGT, respectively. The downstream end of the analyzed V region corresponds to the 5' end of the germline CDR3-IMGT as defined by IMGT/JunctionAnalysis 28 .
Data mining
Output data from IMGT/V-QUEST for all productive IGHV-IGHD-IGHJ rearrangements were parsed, reorganized, and exported to a spreadsheet through the use of computer programming with the Perl programming language. The following information was extracted:
1 .
IGHV gene usage, percentage of identity to the closest germline gene and VH CDR3 length.
.
SHM characteristics: Each nucleotide mutation in every sequence was recorded, as was the change or preservation of the corresponding amino acid, identified as replacement (R) or silent (S), respectively. Amino acids were grouped according to standardized biochemical criteria and based on physicochemical properties (hydropathy, volume, chemical characteristics), as previously described 29 . In order to account for the fact that a mutation is more likely to occur in a VH FR than a VH CDR simply due to greater length, each mutation was 'weighted', or normalized, as recently reported by our group 9 . We extracted additional information on all amino acid changes codon by codon and examined whether the somatically introduced amino acid belonged to the same physicochemical class as the mutating amino acid ("conservative" change) or not ("nonconservative" change) [29] [30] .
Identification of stereotyped rearrangements based on sequence pattern discovery
In order to comprehensively identify possible restrictions in the VH CDR3 amino acid composition of rearrangements utilizing the same IGHV gene, leading to an overall homology between different IGHV-D-J rearrangements, we used the pattern-based method described previously in CLL 11 . For the present analysis, more stringent criteria on top of requiring at least 50% amino acid identity and 70% similarity between stereotyped sequences, were applied, including usage of the same IGHV gene, identical VH CDR3 length, and identical offset of the identified pattern within VH CDR3
sequences of unrelated rearrangements.
The identification of shared patterns led to the clustering of MCL rearrangements on a first (ground) level or level 0. VH CDR3 sequences can appear in more than one ground level cluster highlighting complex relationships, which were used for further clustering at higher levels. 
Statistical analysis
RESULTS
IG gene repertoires
A total of 807 productive IGHV-IGHD-IGHJ rearrangements were amplified. IGHV gene repertoire analysis showed that IGHV3 was the predominant subgroup (416/807, 51.6%), followed by IGHV4 (208/807, 25.8%) (Supplemental Table 1 ). Thirty-eight functional IGHV genes were identified (Supplemental Table 2 Tables 3A and B) .
IGHD genes were identified in 803/807 junctions; IGHD3 and IGHD6 subgroup genes predominated (275 and 163 cases, respectively). Twenty-five IGHD genes were identified (Supplemental Table 4 ), of which IGHD3-3 was the most frequent (81/803 cases, 10.1%). Regarding IGHJ gene usage, the majority of cases utilized the IGHJ4
(353/807 cases; 43.7%) and IGHJ6 (239/807; 29.6%) genes (Supplemental Table 5 ).
The median VH CDR3 length was 16 amino acids (range, and IGHJ6 genes at roughly identical frequencies (~30%) (Supplemental Table 7 ).
Somatic hypermutation analysis
Following the 98% GI cut-off value, which has been adopted in several MCL studies, 186/807 sequences (23%) from our series were defined as "mutated", whereas the remainder (621/807 sequences, 77%) had "unmutated" IGHV genes. However, as outlined in the Introduction, this strategy (irrespective of the actual percentage) has questionable relevance for purposes other than prognostication in CLL.
We therefore adopted a different approach and considered sequences with no somatic hypermutations separately from cases with even a single mutation. By this approach, 238/807 sequences (29.5%) could be assigned to a "truly unmutated" subgroup (100% GI), whereas the remaining sequences (569/807, 70.5%) exhibited some impact of SHM activity, ranging from minimal to pronounced. Mutated cases were further subdivided according to their mutational "load" into successive bins of 1% difference from the closest germline gene (Supplemental Table 8 ). For statistical comparisons, sequences with 97-99.9% GI were classified as "minimally/borderline mutated" (n=458/807; 56.7%), whereas those with <97% GI as "highly mutated" (n=111; 13.8%). The 97% cut-off was an educated choice and, while still essentially arbitrary, does not affect our conclusionsas already mentioned, our critical differentiation to previous approaches is the "isolation" of cases with no mutations.
The IGHV repertoires of the three subgroups described above ("truly unmutated", "minimally/borderline mutated", "highly mutated") were significantly different (Supplemental Table 9 ). For instance, the IGHV3-21 gene was used by 4.4% of rearrangements with <97% GI vs. 22.7% of rearrangements with 100% GI (p<0.01). In sharp contrast, the IGHV3-23 gene was over-represented among rearrangements with <97% GI (20.2%), while only 4.2% of "truly unmutated" rearrangements utilized this gene (p<0.01).
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Significant differences were also identified regarding the "propensity" of certain IGHV genes to acquire somatic hypermutations when utilized in MCL IG receptors (Supplemental Table 10 ). In particular, the IGHV3-23 gene had the highest proportion of "highly mutated" rearrangements (36.7%); in contrast, only a few (ranging from 3-6.4%) IGHV1-8, IGHV3-21 and IGHV4-34 rearrangements were "highly mutated" (Figure 4 ).
Given the distinctive molecular features of IGHV-IGHD-IGHJ rearrangements assigned to each mutational subgroup described above, we next explored whether these features are specific to MCL. To this end, we performed comparisons to CLL and SMZL and identified that the "minimally/borderline mutated" status is significantly more common in MCL vs. either CLL or SMZL (p<0.001 for both comparisons). Additionally, the IGHV gene repertoires of the mutational subgroups differed significantly between the three entities, indicating that the findings reported here are "MCL-specific" (Supplemental Tables 11A and B) .
Characteristics and topology of somatic hypermutation
Analysis of the molecular characteristics and distribution of somatic hypermutations was Table 12 .
Replacement to silent (R/S) mutation ratios were calculated for all cases with less than 100% GI; the overall R/S ratios for FRs and CDRs were 1.75 and 3.69, respectively (Supplemental Table 13 ). In view of the IGHV gene repertoire differences between "minimally/borderline mutated" and "highly mutated" cases reported above, SHM targeting was also investigated independently within each mutational subgroup, focusing
For personal use only. on April 12, 2017. by guest www.bloodjournal.org From on rearrangements utilizing the same IGHV gene (Supplemental Table 14) . Following this approach, significant differences were identified among "minimally/borderline mutated" cases: for instance, IGHV3-21 rearrangements were highly targeted for R mutations in VH CDR1 and VH CDR2, whereas IGHV3-23 rearrangements exhibited a more even distribution of R and S mutations over VH FRs and VH CDRs. Table 15A ; the actual aligned sequences are listed in Supplemental Table 15B .
Pattern discovery in VH CDR3 sequences
Based on shared VH CDR3 sequence patterns and following strict criteria as outlined in
Patients and Methods, 84 of 807 (10.4%) sequences were placed in 38 clusters at the ground level (level 0) with 2 up to 7 sequences each (Supplemental Table 16A ).
Level 0 clusters were characterized by high VH CDR3 amino acid identity and similarity stemming from the usage of identical IGHD and IGHJ genes and, for some clusters, also extending to the presence of shared junctional residues ( Figure 6 ). The common sequences between level 0 clusters led to their grouping in clusters at two progressively higher levels of hierarchy (levels 1-2; Supplemental table 16B); the highest level Table 16A ).
The IGHV gene repertoire differed significantly between clustered vs. non-clustered cases ( Figure 7) . The most striking case concerned the IGHV3-21 and IGHV4-34 genes, which accounted for 67% of clustered cases vs. only 27% of non-clustered cases First, no solid correlations have yet been found between IGHV mutational status and patient survival in MCL [12] [13] [17] [18] . Although certainly of interest, we refrained from exploring potential clinical correlations given the retrospective character of our study and also taking into account that patients were not treated uniformly. Second, perhaps more importantly, on the evidence reported here, the majority of MCL cases indeed carry some level of SHM, which also seems to be distributed in a "disease-biased" manner.
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This important feature was overlooked in previous studies by the use of the 2% identity cutoff, which is biologically questionable and also creates an oxymoron, in that all sequences above the cutoff are considered as "unmutated" even when carrying one or more mutations leading to less than 100% identity to the closest germline gene. Thus, our decision to consider as mutated all cases with any type and number of IGHV gene sequence changes enabled us to obtain a far more accurate view of SHM in MCL.
In particular, a major finding of the present study is that distinct MCL subgroups of different mutational load ("truly unmutated", "minimally/borderline mutated", "highly Since gene-specific patterns of SHM "load" have been reported in other B cell lymphomas, and also in order to explore whether the findings reported here are "disease-biased", we compared the IGHV-IGHD-IGHJ rearrangements from MCL to rearrangements of similar mutational status from CLL 32 or SMZL 33 . We were able to document important differences; again highlighting the unique features of the MCL IG repertoire, especially for cases assigned to the "minimally/borderline mutated" and "truly unmutated" subgroups. Prompted by these findings, we suggest that the paucity or lack of SHM in a significant proportion of MCL cases need not necessarily imply "antigen naivety" but perhaps functional selection for the preservation of the IG gene sequences in germline or near-germline composition, at least in a proportion of cases.
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